Amyris, Inc. (NASDAQ:AMRS) traded up 14.2% during mid-day trading on Friday . The stock traded as high as $3.67 and last traded at $3.53. 731,104 shares were traded during trading, an increase of 181% from the average session volume of 260,584 shares. The stock had previously closed at $3.09.

A number of research firms have weighed in on AMRS. Zacks Investment Research downgraded Amyris from a “buy” rating to a “hold” rating in a research report on Monday, October 23rd. HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of Amyris in a report on Wednesday. Cowen and Company set a $4.00 price objective on Amyris and gave the stock a “hold” rating in a report on Thursday, August 17th. Finally, ValuEngine upgraded Amyris from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company’s stock. Amyris presently has a consensus rating of “Hold” and a consensus price target of $20.69.

The company has a debt-to-equity ratio of -0.76, a current ratio of 0.65 and a quick ratio of 0.56.

Amyris (NASDAQ:AMRS) last announced its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.04). The company had revenue of $24.20 million during the quarter, compared to the consensus estimate of $36.30 million. During the same quarter in the previous year, the company posted ($0.07) EPS. Amyris’s revenue for the quarter was down 8.8% compared to the same quarter last year. research analysts expect that Amyris, Inc. will post -3.32 EPS for the current fiscal year.

Institutional investors have recently bought and sold shares of the business. Bank of New York Mellon Corp boosted its position in Amyris by 16.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 32,768 shares of the biotechnology company’s stock valued at $104,000 after acquiring an additional 4,603 shares in the last quarter. Carl Domino Inc bought a new stake in Amyris during the 3rd quarter valued at approximately $182,000. KBC Group NV boosted its position in Amyris by 228.4% during the 3rd quarter. KBC Group NV now owns 60,154 shares of the biotechnology company’s stock valued at $192,000 after acquiring an additional 41,834 shares in the last quarter. Finally, Tanaka Capital Management Inc. boosted its position in Amyris by 72.0% during the 3rd quarter. Tanaka Capital Management Inc. now owns 528,549 shares of the biotechnology company’s stock valued at $1,691,000 after acquiring an additional 221,295 shares in the last quarter. 19.99% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This article was posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this article on another site, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this article can be viewed at https://theolympiareport.com/2017/11/17/amyris-inc-amrs-trading-14-2-higher.html.

About Amyris

Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.

Receive News & Ratings for Amyris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.